NCT04794088 - Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2021

Primary Completion Date

March 16, 2022

Study Completion Date

April 7, 2022

Conditions

ARDSAcute Respiratory Distress SyndromeCovid19Endothelial DysfunctionPulmonary Edema

Interventions

DRUG

Imatinib Mesylate intravenous solution

A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).

DRUG

Placebo

A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).

Trial Locations (2)

Amsterdam Universitair Medische Centra, location VUmc, Amsterdam

Amsterdam Universitair Medische Centra, location AMC, Amsterdam